Cel Sci Corporation (CVM)

[sunpillar]

Greetings, fellow CVM longs!

I've been holding and buying shares in Cel-Sci, for longer than I care to admit (since about 2007!)

I don't post a lot here, but I do regularly read and follow the board, very closely. I am grateful I bought more shares at around $3.10 recently, prior to the current run-up; so, I'm just over my break-even point, reverse-splits and all.. :)

Long and strong!

Anyway, I have been wondering something for quite a while now, and wanted to bounce it off my fellow investors.


Of all the variables affecting the outcome of the phase III study, there is one thing I have not heard much (if anything) about, and that is:

What might the impact be of the cold-fill Multikine manufacturing facility, on the effect that it has on phase 3, vs phase 2 results?


Whilst the biologic properties & chemistry of Multikine are identical in both studies, the consistency and quality of Multikine should be FAR superior in the current phase 3 trial, as compared to phase 2.

Is it out of the question then, that this improved product quality could potentially be MORE effective, and exceed survival rates observed in phase 2?


Thoughts anyone?

Have a great Easter everyone, and good luck to us all! :)